Dogwood Therapeutics Secures $100M Partnership for Antiviral Assets

Alpharetta, Georgia, USA – April 23, 2026

Dogwood Therapeutics announced a global development and commercialization partnership with PRIDCor Therapeutics for its antiviral assets IMC-1 and IMC-2, in a deal valued at up to $100 million, marking a strategic shift to accelerate pipeline value while focusing internal resources on core pain and neuropathy programs. The agreement enables PRIDCor to take full responsibility for development, regulatory advancement, and commercialization activities, while Dogwood retains significant financial upside through tiered royalties of up to 15% and milestone payments tied to development and regulatory achievements.

Strategic Partnership Unlocks Antiviral Asset Potential

The partnership grants PRIDCor Therapeutics exclusive global rights to develop and commercialize IMC-1 and IMC-2, two investigational antiviral therapies targeting infection-associated chronic illnesses, including Long-COVID and fibromyalgia-related conditions. Under the agreement, PRIDCor will lead clinical development, regulatory submissions, and global commercialization, significantly reducing Dogwood’s operational and financial burden while ensuring continued advancement of these assets.

In return, Dogwood will receive tiered royalties on net sales reaching up to 15%, as well as a share of future development and regulatory milestone payments, with total potential consideration capped at $100 million. Additionally, Dogwood is entitled to 9% of future capital raised by PRIDCor to support the ongoing development of these antiviral candidates, creating a multi-layered revenue opportunity tied to long-term success.

This agreement reflects a growing trend in the pharmaceutical industry, where companies leverage strategic licensing partnerships to maximize asset value while optimizing resource allocation.

Focus Shift Toward Core Pain and Neuropathy Pipeline

As part of its broader corporate strategy, Dogwood is refocusing its internal efforts on advancing its lead programs, including Halneuron® (a NaV 1.7 inhibitor) and SP16 IV, both targeting chronic pain and chemotherapy-induced neuropathy. Halneuron®, currently in Phase 2b clinical development, has already received FDA Fast Track designation, highlighting its potential as a non-opioid treatment for neuropathic pain.

SP16 IV, a low-density lipoprotein receptor-related protein-1 (LRP1) agonist, is being developed for its anti-inflammatory and tissue-repair properties, with a Phase 1b trial supported by the National Cancer Institute. By divesting operational responsibility for its antiviral assets, Dogwood can prioritize capital and scientific focus on these high-value programs, enhancing its position in the pain management and oncology supportive care markets.

This strategic reallocation underscores Dogwood’s commitment to developing innovative, non-opioid therapies in areas of significant unmet medical need.

Industry Implications and Future Outlook

The collaboration between Dogwood and PRIDCor highlights the increasing importance of partnership-driven drug development models, particularly in areas such as antiviral therapies and chronic disease management. By combining PRIDCor’s expertise in infection-related chronic illnesses with Dogwood’s innovative antiviral assets, the partnership aims to accelerate clinical progress and bring new treatment options to patients more efficiently.

The deal also reflects broader industry dynamics, where biotech companies seek to balance innovation with financial sustainability, leveraging partnerships to mitigate risk while maintaining long-term value creation. With potential milestone payments, royalties, and equity-linked benefits, Dogwood stands to gain significant financial returns if the antiviral programs succeed commercially.

As the global demand for effective antiviral therapies continues to grow, particularly in the context of Long-COVID and post-viral syndromes, this partnership positions both companies to capitalize on emerging therapeutic opportunities while advancing the next generation of treatments.

With strong financial backing, strategic collaboration, and a differentiated technology platform, Atrium Therapeutics is well-positioned to drive the next wave of innovation in cardiovascular medicine, bringing novel, precision therapies closer to patients in need.

Source: Dogwood Therapeutics press release